On 7 September 2026, CREALIGHTS (01191.HK) announced that it has been included in the eligible securities lists under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes effective the same date, allowing eligible Mainland investors to trade its shares directly through the Shanghai and Shenzhen exchanges; the Company will continue to deepen its presence in the optoelectronic interconnectivity field.
on September 7, 2026, the robotics theme strengthened, with UBTECH ROBOTICS (09880.HK) fluctuating higher. As of 13:25, the company's quote stood at HKD 87.200, up 1.81%.
On 7 September 2026, BIDU-SW (09888.HK) announced that its Class A ordinary shares have been included as eligible securities under the Shenzhen-Hong Kong Stock Connect effective the same date (following their inclusion under the Shanghai-Hong Kong Stock Connect announced on 4 September), marking an important step in expanding to Mainland China investors.
On 7 September 2026, ASCLETIS-B (01672.HK) announced that its ordinary shares have been included in the eligible securities lists under the Stock Connect schemes effective the same date, allowing eligible Mainland investors to trade the Company's shares through the Stock Connect channel.
On 7 September 2026, VIEWTRIX TECH (03310.HK) announced that its H shares have been included in the eligible securities lists under Stock Connect with effect from the same date, allowing eligible Mainland investors to invest directly in its H shares through the Shanghai and Shenzhen exchanges, which will help broaden its investor base and potentially enhance liquidity.
On 7 September 2026, HENLIUS (02696.HK) announced that it has been included in the eligible securities lists under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect, formally effective the same date, which will help broaden its shareholder base and enhance the trading liquidity of its shares.
On 7 September 2026, TONGGUAN GOLD (00340.HK) announced that, pursuant to notices published by the Shanghai and Shenzhen stock exchanges, its shares have been included in the securities lists under Stock Connect effective the same date.
On 7 September 2026, HQVT (01392.HK) announced that its H shares have been included in the eligible securities lists under Stock Connect (Shanghai-Hong Kong and Shenzhen-Hong Kong) effective the same date, allowing eligible Mainland investors to invest directly in its H shares through the Shanghai and Shenzhen exchanges; the Company is a multi-spectral AI technology enterprise in China.
On 7 September 2026, HBM HOLDINGS-B (02142.HK) announced that its shares have been added to the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect lists, effective 7 September 2026, enabling direct investment by qualified mainland Chinese investors through the Stock Connect mechanism.
On 7 September 2026, TENNOR THERAP-B (06872.HK) reported positive Phase IIa proof-of-concept data for rifaquizalone (TNP-2092) in prosthetic joint infection. Based on these data, a multicenter Phase IIb trial has been approved by the NMPA and recently initiated.
On 7 September 2026, CSTONE PHARMA-B (02616.HK) announced that its shares have been added to the Stock Connect eligible list, effective 7 September 2026. CEO Dr. Yang Jianxin stated that the inclusion is expected to broaden the investor base and enhance liquidity. Core asset CS2009 trispecific antibody is advancing in global Phase I/II, with the first global Phase III registrational trial expected to start before end-2026.
On 6 September 2026, FOSUN PHARMA (02196.HK) announced that its subsidiary Fosun Pharma Singapore sold 9.897 million shares (6.00%) of India's Gland Pharma on 4 September 2026 for approximately USD 294 million, at a 2.72% discount to the previous closing price. Post-transaction, the group's stake falls to approximately 45.76% while it remains the controlling shareholder; proceeds are designated for R&D investment, share buybacks and debt repayment, with settlement expected on 7 September 2026 India time.
On 6 September 2026, PICC GROUP (01339.HK) approved the nomination of Ms. Yang Dongning as a candidate for executive director of the fifth session of the Board.
On 6 September 2026, KEYMED BIO-B (02162.HK) announced that Dr. Wang Minchuan has resigned as a non-executive director, effective 4 September 2026, to focus on other commitments, confirming no disagreement with the Board and no matters requiring shareholder or exchange attention.
On 7 September 2026, KINTOR PHARMA-B (09939.HK) announced the completion of the long-term safety trial of KT-939, a novel tyrosinase inhibitor, on 4 September 2026, with no skin adverse reactions observed among 114 subjects after 52 weeks of continuous use of 0.2% KT-939.
On 7 September 2026, RIVERINE CHINA (01417.HK) announced that its public float stood at approximately 23.85%, below the 25% minimum required by the Listing Rules, after 8,218,000 shares (approximately 2.03% of issued share capital) held by the share award scheme trustee were excluded from the public float. The company is considering options including trustee share sales and/or a new share issuance to the public, and expects to restore the public float within 6 months.
